Calendario›AMGN›Inebilizumab

Inebilizumab

Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor

Ensayo de AMGEN INC en Highly Sensitized Patients on Waiting List for Kidney Transplantation (del registro, en inglés).

Fase

Fase 2

Estado

Retirado antes de empezar

Centros

2

Fin del objetivo primario

dic 2021

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, abierto. Comenzó en dic 2019.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Stopped due to no enrollment».

Qué mide

Number of subjects with safety events (treatment-emergent adverse events, treatment-emergent serious adverse events, or treatment-emergent adverse events of special interest) during the course of the study (Through study completion, an average of 1 year) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroViela Bio is conducting an open-label, randomized study of inebilizumab, VIB4920, or the combination as part of a multi-center study in highly sensitized patients on the deceased donor waiting list for kidney transplantation. Eligible subjects will be randomized to one of three treatment arms, administered the investigational products as an intervention and subsequently followed for safety.

Más ensayos de AMGN

Todos los de AMGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT04174677), actualizada en jun 2024.